These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2483466)

  • 21. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
    Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy.
    Mandanas RA; Saez RA; Selby GB; Confer DL
    Am J Hematol; 1996 Feb; 51(2):104-11. PubMed ID: 8579049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.
    Przepiorka D; Ippoliti C; Panina A; Goodrich J; Giralt S; van Besien K; Mehra R; Deisseroth AB; Andersson B; Luna M
    Bone Marrow Transplant; 1994 Apr; 13(4):461-4. PubMed ID: 8019472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylaxis of CMV infection in bone marrow transplant recipients by hyperimmune CMV gamma-globulin.
    Condie RM; O'Reilly RJ
    Dev Biol Stand; 1982; 52():501-13. PubMed ID: 6299859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ; Ho WG; Bartoni K; Champlin RE
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products.
    Rubie H; Attal M; Campardou AM; Gayet-Mengelle C; Payen C; Sanguignol F; Calot JP; Charlet JP; Robert A; Huguet F
    Bone Marrow Transplant; 1993 Mar; 11(3):209-14. PubMed ID: 8385522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid detection cytomegalovirus pneumonia in recipients of bone marrow transplant: evaluation and comparison of five survey methods for bronchoalveolar lavage fluid.
    Goto H; Yuasa K; Sakamaki H; Nakata K; Komuro I; Iguchi M; Okamura T; Ieki R; Tanikawa S; Akiyama H; Onozawa Y; Mochida Y
    Bone Marrow Transplant; 1996 May; 17(5):855-60. PubMed ID: 8733709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Specific anti-cytomegalovirus immunoglobulins in the prevention of cytomegalovirus infections in bone marrow allografts].
    Huart JJ; Baume D; Jouet JP
    Ann Med Interne (Paris); 1987; 138(5):372-4. PubMed ID: 2823667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
    Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
    Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of cytomegalovirus pneumonia after bone marrow transplantation with cytomegalovirus immunoglobulin combined with ganciclovir.
    Verdonck LF; de Gast GC; Dekker AW; de Weger RA; Schuurman HJ; Rozenberg-Arska M
    Bone Marrow Transplant; 1989 Mar; 4(2):187-9. PubMed ID: 2539877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
    Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
    Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prevention and treatment of cytomegalovirus infections after graft of allogenic bone marrow].
    Gluckman E; McMazeron ; Keable H; Meletis J; Bombail D; Jolivet I; Huart JJ; Nebout T; Cavazzana M; De Castro H
    Nouv Rev Fr Hematol (1978); 1987; 29(1):17-21. PubMed ID: 3035485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
    Narvios AB; Lichtiger B
    Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group.
    Prentice HG; Gluckman E; Powles RL; Ljungman P; Milpied NJ; Camara R; Mandelli F; Kho P; Kennedy L; Bell AR
    Bone Marrow Transplant; 1997 Jan; 19(2):129-33. PubMed ID: 9116609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ganciclovir in the treatment of cytomegalovirus pneumonitis in bone marrow transplant recipients.
    Milliken S; Powles R; Ettinger N; Gallagher C; Jameson B; Tryhorn Y; Stern H; Selby P
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3110-1. PubMed ID: 2539692
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
    Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
    Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience.
    Slavin MA; Meyers JD; Remington JS; Hackman RC
    Bone Marrow Transplant; 1994 May; 13(5):549-57. PubMed ID: 8054907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT.
    Ljungman P; De Bock R; Cordonnier C; Einsele H; Engelhard D; Grundy J; Locasciulli A; Reusser P; Ribaud P
    Bone Marrow Transplant; 1993 Oct; 12(4):399-403. PubMed ID: 8275040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.